Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

60 Degrees Pharmaceuticals (SXTPW) Other Operating Expenses (2022 - 2024)

Historic Other Operating Expenses for 60 Degrees Pharmaceuticals (SXTPW) over the last 3 years, with Q3 2024 value amounting to $16623.0.

  • 60 Degrees Pharmaceuticals' Other Operating Expenses rose 12358.21% to $16623.0 in Q3 2024 from the same period last year, while for Jun 2025 it was $16623.0, marking a year-over-year increase of 13271.86%. This contributed to the annual value of -$163228.0 for FY2024, which is N/A changed from last year.
  • 60 Degrees Pharmaceuticals' Other Operating Expenses amounted to $16623.0 in Q3 2024, which was up 12358.21% from $19684.0 recorded in Q2 2024.
  • In the past 5 years, 60 Degrees Pharmaceuticals' Other Operating Expenses ranged from a high of $19684.0 in Q2 2024 and a low of -$70490.0 during Q3 2023
  • Over the past 3 years, 60 Degrees Pharmaceuticals' median Other Operating Expenses value was $730.0 (recorded in 2023), while the average stood at -$17033.4.
  • In the last 5 years, 60 Degrees Pharmaceuticals' Other Operating Expenses soared by 10141.16% in 2023 and then soared by 259643.84% in 2024.
  • Over the past 3 years, 60 Degrees Pharmaceuticals' Other Operating Expenses (Quarter) stood at -$51714.0 in 2022, then crashed by 36.31% to -$70490.0 in 2023, then skyrocketed by 123.58% to $16623.0 in 2024.
  • Its Other Operating Expenses was $16623.0 in Q3 2024, compared to $19684.0 in Q2 2024 and -$70490.0 in Q3 2023.